You are here

Article Text

Article menu
Download PDFPDF
DTB drug review
Naldemedine for opioid-induced constipation

Abstract

Generic name: Naldemedine tosylate

Brand name: Rizmoic

Formulation: 200 mcg film-coated tablets

Market Authorisation holder: Shionogi B.V

Indication: Treatment of opioid-induced constipation in adult patients who have previously been treated with a laxative

Dose: 200 mcg/day, taken at the same time every day. Naldemedine may be used with or without a laxative. It must be discontinued if treatment with the opioid is discontinued.

Cost: £41.72 for 28 tablets

Classification: Prescription only medicine subject to additional monitoring (▼)

  • constipation
  • chronic pain

https://doi.org/10.1136/dtb.2021.000063

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Written by the DTB team; externally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.